Biotechnology

With backing from AstraZeneca and Pfizer, Beijing’s Syneron Bio is using its AI-driven platform to develop novel drugs for cancer and chronic illness.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

A Minnesota startup has secured major funding to advance its bioelectronic device aimed at the brain's waste clearance system for treating CNS disorders.

As pharma sells GLP-1s directly to patients, doctors are split on the new model. Is it a lifeline for access or a risk to integrated patient care?

Eight top US students will join a fully funded internship in Copenhagen to learn from Denmark's world-class sustainability, forging a new path for green careers.

The biotech upstart will present a bold pipeline, including a head-to-head trial against a market leader and a first-in-class autoimmune eye disease therapy.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

A new FDA approval for an EGFR-mutated lung cancer therapy cuts treatment from hours to minutes, offering new hope and convenience for thousands of patients.

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

Celltrion's SteQeyma autoinjector gets a CHMP nod, enhancing patient care and intensifying competition in Europe's crowded biosimilar market.

Bolstered by positive clinical data and top investors, Kalaris Therapeutics extends its runway to advance TH103, a next-gen treatment for neovascular AMD.

A Utah biotech reports promising results for a novel mRNA therapy that makes cancer cells look like measles, setting the stage for crucial animal trials.

Early Phase 1a data for Kalaris's new nAMD drug shows significant vision improvement and potential for extended durability, aiming to reduce patient burden.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

As the market for oral supplements explodes, products like Synadentix promise a healthier mouth. But does the science back the billion-dollar marketing?

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.

As biotech and pharma risks evolve, Verist Inc. launches tailored coverage, aiming to redefine insurance with a high-touch, data-driven service model.